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Abstract
Background: Autoantibodies to the human muscarinic acetylcholine receptor of the M3 type (hmAchR M3) have been
suggested to play an etiopathogenic role in Sjögren's syndrome. Primary biliary cirrhosis (PBC) often is associated with
this syndrome. Therefore, we studied the co-presence of hmAchR M3 autoantibodies in patients with PBC.
Methods: Frequency of hmAchR M3 autoantibodies was assessed by Western blotting analysis as well as by an
ELISA using a 25-mer peptide of the 2
nd extracellular loop of hmAchR M3. Co-localization of hmAchR M3/PBC-
specific autoantibodies was studied by confocal laser scanning microscopy. Finally, sera from patients with PBC as
well as from healthy controls were tested.
Results: Western blotting analysis as well as results from ELISA testing revealed a significantly enhanced IgG
reactivity in PBC patients in contrast to healthy controls. Co-localization of autoantibodies with the hmAchR M3
receptor-specific autoantibodies was observed in 10 out of 12 PBC-patients but none of the 5 healthy controls.
Antibodies of the IgM type were not found to be affected.
Conclusions: For the first time, our data demonstrate the presence of autoantibodies to the hmAchR M3 in PBC
patients. These findings might contribute to the understanding of the pathogenesis of this disease. Further studies
have to focus on the functionality of hmAchR M3 autoantibodies in PBC patients.
Background
Primary biliary cirrhosis (PBC) is an autoimmune liver dis-
ease characterized by chronic progressive destruction of the
small intrahepatic bile ducts [1-4]. Its etiopathogenesis still
remains unclear, although (i) genetic disposition, (ii) micro-
organisms, (iii) apoptotic processes, as well as (iv) environ-
mental factors have been suggested to be of relevance for
both development and maintenance of PBC [2,5-10].
Diagnostically, antimitochondrial antibodies (AMA)
which mainly target the different subunits of the pyru-
vate dehydrogenase complex (PDC) play an important
role and have been shown to occur in about 90% of all
PBC patients [1-3,11]. However, these antibodies do not
meet the classical criteria for an autoantibody-mediated
autoimmune disease [12-15], i.e., induction of the
disease in animal models by passive transfer of the dis-
ease-specific antibodies or via the application of the tar-
get antigen and the recovery from the disease due to a
reduction of the titers of the disease-specific antibodies
[3,16-19]. Therefore, the PDC-specific antibodies seem
to be of no etiopathogenic relevance. Furthermore, since
PDC is an antigen expressed in almost all cell types they
do not explain the organ-specificity of PBC.
Deduced from recent studies on other autoimmune dis-
orders, a novel etiopathogenic concept has been developed
which is based on the involvement of functionally active
autoantibodies against neurotransmitter receptors [20]. As
an example, patients with Pemphigus vulgaris exhibit auto-
antibodies to the alpha-9-acetylcholine-receptor which are
responsible for the typical acantholysis [21]. In addition,
experimental and clinical studies verify the pathogenic role
of antibodies to the beta1-adrenergic receptor in dilatative
cardiomyopathy [22]. Furthermore, in patients suffering
* Correspondence: christoph.berg@med.uni-tuebingen.de
Department of Internal Medicine I, Medical Clinic, University of Tübingen,
Germany
Berg et al. BMC Gastroenterology 2010, 10:120
http://www.biomedcentral.com/1471-230X/10/120
© 2010 Berg et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.from myasthenia gravis, autoantibodies to the alpha-1 sub-
unit of the nicotinic acetylcholine receptor in muscles
were shown to disturb neuromuscular signal transduction
and mark the cells for complement mediated lysis [23].
Interestingly, also in patients with M. Sjögren, an autoim-
mune disease quite often being associated with PBC
[24,25], autoantibodies to human muscarinic acetylcholine
receptors (hmAchR) of the M3 type were suggested to be
one factor responsible for disease induction [26,27]. More-
over, since this specific receptor subtype was also detected
on biliary cells but not on hepatocytes [28,29] we hypothe-
sized that hmAchR M3-specific autoantibodies could play
an important role in the etiopathogenesis of PBC. Thus,
we now have undertaken a comprehensive study analyzing
whether autoantibodies to the hmAchR of the M3 type
could also be found in patients with PBC.
Methods
Patients
Our well-characterized PBC cohort at University Hospital
Tübingen encompasses 50 patients (42 female, 8 male);
furthermore, also 16 healthy controls gave their informed
consent for this study, which was approved by the local
ethics committee.
PBC patients: mean age was 57.7 ± 10.8 years (range
27 - 74 years); all patients exhibited typical PBC-
associated laboratory parameters (such as elevated levels
of alkaline phosphatase (AP), γ-glutamyltransferase
(gGT), and/or IgM values). Liver biopsies had been per-
formed in 23 patients and demonstrated PBC-specific
lesions in all instances. 48 patients showed a positive
reaction in the immunofluorescence test (IFT) to mito-
chondrial antigens on cryostat sections (AMA-positivity);
in the remaining 2 AMA-negative patients PBC was evi-
denced either by liver biopsy or the presence of anti-
PDC-antibodies by Western blotting analysis. 20 patients
showed ANA (anti-nuclear antigen) reactivity in the IFT.
13 patients exhibited SMA (smooth muscle antigen)
reactivity in the IFT. Elevation of IgM globulins were
observed in 37 patients (>230 mg/dl) and elevation of
IgG levels in 14 patients (>1.600 mg/dl). 44 patients were
under therapy with ursodeoxycholic acid.
Controls: sera from 16 healthy blood donors from the
University Hospital Tübingen were included in our
study (female-to-male ratio was 10:6; mean age: 32 ± 8
years; range 20 - 48 years). All sera were checked for
autoantibody reactivity by the IFT and were found to be
serologically negative for AMA. 3 patients showed auto-
antibodies to ANA and another 3 patients to SMA.
Confocal Laser Scanning Microscopy
Co-localization of PBC-specific antibodies with autoan-
tibodies to the hmAchR M3 was studied using a Leica
TCS SP2-x1 confocal laser scanning microscope and
'Leica confocal' software (Leica Biosystems GmbH,
Nussloch, Germany). For this purpose, HT-29 human
colon carcinoma cells were cultured in RPMI-1640
medium (BioWhittaker, Verviers, Belgium) supplemen-
ted with 10% heat-inactivated fetal calf serum (PAA
Laboratories, Cölbe, Germany), 100 units of penicillin/
ml, 0.1 mg streptomycin/ml and 10 mM HEPES (all
from Gibco, Karlsruhe, Germany). Cells were grown at
37 °C in a 5% CO2 atmosphere and maintained in the
log phase. Using a polyclonal anti-hmAchR M3 anti-
body, HT-29 cells were tested by Western blot ana-
lyses for expression of hmAchR of the M3 type (data
not shown). They were seeded at 5 × 10
5/ml in 24
wells plates containing a sterile cover slip. Cells were
allowed to adhere overnight and then washed twice
with PBS (Gibco). Cells were fixed with 500 μlo f3 . 7 %
paraformaldehyde (Sigma, Deisenhofen, Germany) for
20 min at room temperature (RT) followed by three
washing steps with 1 ml PBS/0.5% BSA (P-BSA), and
blocking for 10 min in PBC/10% FCS at RT. After
washing once with P-BSA, cells were permeabilized
with 0.1% Triton X-100 (Roth, Karlsruhe, Germany)
for 10 min at RT, washed three times with P-BSA.
Labelling with primary antibodies (50 μl; 60 min at
RT) employed (i) a rabbit anti-hmAchR M3 polyclonal
antibody (poAb; Acris, Hiddenhausen, Germany), (ii) a
mouse anti-Na
+/K
+-ATPase mAb (Biomol, Hamburg,
Germany) and serum IgG fractions from (iii) PBC
patients or (iv) healthy controls. Serum IgG from the
respective individuals was purified as described [30]
and diluted in PBS/1% BSA to a final concentration
(f.c.) of 2.5 μg/ml.
After washing with P-BSA for three times, 50 μlo ft h e
secondary antibodies (goat anti-rabbit IgG, Alexa Fluor
488 conjugated (Invitrogen, Karlsruhe, Germany); goat
anti-mouse IgG, Cy3 conjugated (Amersham Pharmacia,
Freiburg, Germany); goat anti-human IgG, Alexa 633
conjugated (Invitrogen)) were added at a f.c. of 2 μg/ml
in P-BSA for 30 min at RT in the dark. After three wash-
ing steps, cells were mounted on a slide (Langenbrinck,
Emmendingen, Germany) using 7 μlm o u n t i n gm e d i u m
(Confocal-Matrix, Micro Tech Lab, Graz, Austria).
Enzyme linked immunosorbent assay (ELISA)
Sera were tested employing a 25-mer peptide ([31-33];
synthesized by Seqlab, Göttingen, Germany; amino acids
213 - 237, KRTVPPGECFIQFLSEPTITFGTAI; concen-
tration of 10 μg/ml) of the hmAchR M3 protein by
ELISA according to the method described [34,35]. Sera
were diluted 1:100 [36,37]. The secondary anti-human
IgG or IgM antibodies (Dianova, Hamburg, Germany)
were used at a concentration of 0.5 μg/ml. The cut-off
values were defined as the mean of the values from the
16 controls in addition to 2 standard deviations.
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Sera were analyzed for the presence of autoantibodies to
the hmAchR of the M3 type using membrane fractions
of hmAchR M3 expressing Sf9 cells (Sigma, Deisenho-
fen, Germany) by Western blotting analysis following
the method described [30,38]. Sera were diluted 1:200 in
5% milk powder (low fat; Roth, Karlsruhe, Germany) in
TBST (10 mM Tris-HCl pH 7.4, 100 mM NaCl, 0.01%
Triton). As secondary antibody horse radish peroxidase-
conjugated anti-human IgG (1:4.000; DAKO, Hamburg,
Germany) was used. Proteins were detected by the
enhanced chemoluminescence (ECL) method (Amer-
sham-Buchler, Germany).
Statistics
Differences between the sera of the patient or control
cohorts concerning reactivity to (i) the hmAchR of the
M3 type or (ii) the 25-mer peptide were statistically
evaluated using the Wilcoxon test (WinSTAT software);
p ≤ 0.05 was defined as significant.
Results
Co-localization of the PBC-specific autoantibodies with
autoantibodies to the hmAchR M3
In order to investigate the presence of human muscarinic
acetylcholine receptor M3 (hmAchR M3)-specific auto-
antibodies in PBC patients, we first addressed the ques-
tion whether PBC-specific antibodies do co-localize with
antibodies to the hmAchR M3. Therefore, HT-29 human
colon carcinoma cells expressing the hmAchR M3 recep-
tor (proven by Western blotting; data not shown) were
fixed on cover slides and stained with sera from PBC
patients (representative ex a m p l eg i v e ni nF i g u r e1 ,
lane A), or control sera IgG fractions from healthy
donors (Figure 1, lane B) as well as a commercially avail-
able polyclonal antibody to the hmAchR M3 (Figure 1,
lanes A+B, column 2); as a control for cell surface recep-
tor staining, a Na
+/K
+-ATPase-specific antibody was
used (Figure 1, lane C, column 3).
As a result, overlaying of the hmAchR M3-specific anti-
body staining with staining by sera from PBC patients
( F i g u r e1 ,l a n eA ,c o l u m n4 )w a sf o u n dt oe x h i b i tap r o -
found co-localization of detected antigens. In clear con-
trast, no co-localizing signals were found for the serum
IgG fractions of healthy donors (Figure 1, lane B, column
4). In total, co-localization of PBC-specific antibodies
with the hmAchR M3-specific antibody was found to be
present in 10 out of 12 tested PBC sera, but none of the
tested control sera (Tab. 1).
In contrast to the staining with the Na
+/K
+-ATPase-
specific mAb (Figure 1, lane C, column 3), staining by
the polyclonal hmAchR M3 antibody was not restricted
to the cell membrane; an additional diffuse intracellular
staining was detectable (Figure 1, lanes A+B, column 2).
Presence of autoantibodies to the hmAchR of the M3
type in sera of PBC patients
To assess whether PBC patients produce autoantibodies to
the hmAchR of the M3 type, we next performed a
Western blotting analysis using the membrane fraction of
Sf9 cells over-expressing the recombinant hmAchR recep-
tor protein (rhM3R) of the M3 type (Figure 2). While all
sera from four initially analyzed PBC patients clearly
detected the typical bands of the PDC complex (Figure 2,
left lanes), hmAchR M3 receptor protein was recognized at
65 kDa by only 2 of the 4 PBC sera (Figure 2, right lanes).
Employment of a control serum from a healthy donor did
n o ts h o wa n yp r o m i n e n tb a n d( F i g u r e2 ,r i g h tp a n e l ) .
Testing a larger cohort of PBC patients, we found a sig-
nificantly elevated frequency of IgG type-autoantibodies
to the recombinant hmAchR M3 receptor protein in sera
from PDC-E2
+ PBC patients 33%) versus the control
group comprising healthy donors (7.7%) (Tab. 2). As an
exception, only one healthy control displayed a hmAchR
M3-specific band, while, as expected, none of the differ-
ent subunits of the PDC was recognized by the same
serum (data not shown).
Frequency of hmAchR M3-specific autoantibodies in the
sera of patients with PBC
The frequency of autoantibodies to hmAchR M3
receptor was also assessed by an ELISA using a 25-mer
peptide of the 2
nd extracellular loop of hmAchR M3,
which has been suggested as the most important epi-
tope of this receptor protein [31-33] (Figure 3). As a
result, we observed a significant difference in IgG reac-
tivity between the PBC patient cohort and healthy con-
trols (Figure 3; bar 1 vs.b a r3 ) .
With respect to the elevated frequency of anti-hmAchR
M3 IgM-type reactivity in PBC patients (Figure 3; bar 2)
we also investigated the control cohort for IgM-type
hmAchR M3-specific autoantibodies. However, there was
no significant difference in the IgM antibody binding
between the PBC patients and the healthy controls
(Figure 3; bar 2 vs. bar 4).
Differences between the PBC patients being ELISA
positive or negative could not be found depending upon
the demographic data. However the ELISA positive
patients showed a heightened number of patients with
elevated IgG (64%) and IgM (91%) levels as compared to
the ELISA negative patients (enhanced IgG level: 18%,
enhanced IgM level: 69%). With respect to the disease
activity we observed that the histologies performed in 6
of the 11 ELISA positive patients, 3 patients showed a
disease stage I-II and 3 patients a disease stage III-IV. In
17 out of the 39 patients being ELISA negative histolo-
gies were performed from which 12 patients showed a
disease stage I-II and 3 patients a disease stage III-IV,
while 2 patients were graded as stage II-III.
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Autoantibodies to neurotransmitter receptors seem to
be involved in the etiopathogenesis of a variety of auto-
immune diseases [21-23,26,27]. There are several reports
on in vitro and in vivo studies suggesting a role for
autoantibodies to the hmAchR M3 subtype in the etio-
pathogenesis of the Sjögren's syndrome which often is
associated with PBC [26,31,39,40]. This hypothesis is
underlined by animal models employing non-obese dia-
betic (NOD) mice, which are well-known for hypofunc-
tion of their salivary glands. Passive transfer of
monoclonal antibodies binding specifically to the rat
mAchR M3 receptor protein into NOD-scid mice
revealed a further diminished secretory function of these
glands [41]. In contrast, mice of the Igμ-null-NOD
strain (completely lacking functionally active B lympho-
cytes) do not exhibit any such glandular dysfunction
while passive transfer of IgG fraction from patients with
M. Sjögren lead to a loss of secretory function [42] and
hmAchR M3-spec. poAb
hmAchR M3-spec. poAb  PBC serum IgG
control serum IgG
Na+/K+-ATPase-spec. mAb
A
B
C
Figure 1 Co-localization of hmAchR M3-specific antibodies with patient-derived PBC-specific antibodies. Confocal laser scanning
microscopy detecting co-localization of a hmAchR M3-specific antibody with patient-derived PBC-specific antibodies. HmAchR M3-positive HT-29
human colon carcinoma cells were fixed and stained with a hmAchR M3-specific polyclonal antibody (poAb) (lanes A+B, column 2) or the serum
IgG fractions of a representative PBC patient (lane A, column 3) or a healthy control (lane B, column 3). As a positive control for cell surface
receptor staining, also a Na
+/K
+-ATPase-specific mAb (lane C, column 3) was used. Magnification: 630×. Provided are the transmission (column 1),
fluorescence data (columns 2+3) as well as the overlay (column 4) of the different photographs. The white arrows show the co-localization of
both antibodies as indicated by the yellow color.
Table 1 Summary of the results of the confocal laser
scanning microscopy*
tested
(n)
positive overlays
(n)
PBC patients 12 10
healthy controls 5 0
*Co-localization of autoantibodies present in the serum IgG fractions of PBC
patients and healthy controls being detected with a polyclonal antibody to
the hmAchR M3 (studied on hmAchR M3-positive HT-29 human colon
carcinoma cells).
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mice diminished it. Concluding from this, autoantibo-
dies to the hmAchR M3 receptor protein are suggested
to be responsible for diminished secretion of the sali-
vary gland cells due to an autoantibody-mediated desen-
sitization of the receptor via internalization or
degradation [43-45].
In our study, we now describe a hitherto unknown co-
localization of IgG-type autoantibodies specific to the
hmAchR M3 found in the sera of patients with PBC,
but not in sera of healthy controls (Figure 1). Of note,
not only cell surface membranes were found to be
stained by our polyclonal hmAchR M3 antibody; addi-
tionally, a diffuse intracellular staining was detectable
(Figure 1, lanes A+B, column 2). This effect was not
found to be unspecific: employment of three different
hmAchR M3-specific antibodies recognizing either (i)
the intracellular C-terminus (as used for Figure 1), (ii)
the extracellular N-terminal sequence or (iii) the 3
rd
intracellular domain of the receptor did not change this
pattern (data not shown). Therefore, our finding may be
in accordance with reports demonstrating internalization
of the hmAchR M3 receptor protein [44,45].
Our further results now report a frequency of
hmAchR M3-specific autoantibodies in PBC patients in
the range of 22-33% (depending upon the detection
technique and materials used). Interestingly, these data
are comparable with data obtained from the literature
for patients with Sjögren's syndrome, in whom autoanti-
bodies were detected by ELISA in a frequency range of
9-40% [32,33,37]. In our study we tested the presence of
these antibodies not routinely but only in patients with
clinical features of M. Sjögren.T h u s ,i d e n t i f y i n go n l y
one patient with typical symptoms of M. Sjögren,t h i s
patient was found to express anti SS-A/SS-B antibodies
as detected by ELISA (data not shown). Interestingly,
this patient also showed hmAchR M3-specific autoanti-
bodies. Further studies have to show if there is a corre-
lation between anti SS-A/SS-B reactivity and the
occurrence of hmAchR M3-specific autoantibodies in
PBC patients.
Our observation that autoantibodies to the hmAchR M3
receptor protein could be detected more frequently in
Western blotting analysis than in the ELISA system (33%
vs. 22%) may be due to the fact that in case of Western
blotting the whole receptor molecule was used providing a
variety of potential epitopes as compared to the peptide
used for detection in the ELISA-based assay. Thus, the
amino acid sequence of the 2
nd extracellular loop as pre-
sented in our 25-mer peptide seems to represent not the
only epitope, although in the Western blotting analysis a
cross-reactivity of autoantibodies to similar muscarinic
receptors cannot be excluded completely.
The comparison of the demographic, clinical and bio-
chemical parameters of the patients being anti-M3R
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Figure 2 Detection of hmAchR M3 autoantibodies in sera of
PBC patients by Western Blot analysis. Detection of
autoantibodies to the recombinant human muscarinic acetylcholine
receptor M3 (M3R) in the sera from PBC patients was revealed by
Western blot analysis. M3R was derived from the membrane fraction
of M3R over-expressing Sf9 cells (0.5 μg/lane). PDC (1 μg/lane) was
used as control for the PBC sera. Sera were diluted 1:200 and
visualized by the anti-human IgG secondary antibody. Given are
exemplary the blots of two sera with positive (PBC-1 and 2) and
two sera with negative results (PBC-3 and 4) to the M3R, as well as
one negative control.
Table 2 Frequency of IgG type-autoantibodies to the
recombinant hmAchR M3 receptor protein in sera from
PDC-E2
+ PBC patients and healthy controls*
Tested
(n)
positive
(n)
positive
(%)
PBC patients 27 9 33**
healthy controls 13 1 7.7
*analyses were performed by Western blotting using the membrane fraction
of hmAchR M3 over-expressing Sf9 cells;
**significantly different from the controls (p = 0.043; Wilcoxon test).
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Figure 3 Detection of hmAchR M3 autoantibodies in sera of
PBC patients by ELISA. Frequency of hmAchR M3-specific
autoantibodies in sera of PBC patients (n = 50) and healthy controls
(n = 16) were detected by ELISA: antibodies of the IgG- and IgM-
type to the 25-mer peptide of the 2nd extracellular loop of the
hmAchR M3. *p < 0.05 as compared to the healthy controls
(Wilcoxon test).
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that the anti-M3R antibodies might occur more fre-
quently in patients with an advanced disease. Since,
however, in quite a lot of them no biopsies were per-
formed, this observation has to be evaluated in more
detail in further studies.
Importantly, hmAchR M3-specific autoantibodies have
not been investigated in PBC before. There are, how-
ever, two reports on the autoantibody response to nico-
tinic acetylcholine receptors [46,47] demonstrating the
recognition of these proteins by the respective autoanti-
bodies in the majority of the PBC patients as well as
patients with myasthenia gravis.
Taken together, our studies show again the presence
of new specific autoantibodies in PBC patients different
to AMA. Since AMA failed to be clearly related to the
etiopathogenesis of PBC it is encouraging that several
new antibodies have been characterized, which might be
associated with disease stage [48] or with new concepts
for the etiopathogenesis of PBC [49].
Conclusions
With respect to the literature and our own data, our con-
cept of the expression of autoantibodies to the muscarinic
A c h Ro ft h eM 3t y p ei np a t i e n t sw i t hP B Cc o u l db eo f
importance for the etiopathogenesis of PBC: (i) for the
first time, our findings may explain the organ-specificity of
the PBC disease since the hmAchR M3 is not expressed
on hepatocytes but on cholangiocytes [29]; in addition,
also the parasympathetic innervation of the biliary system
may point to a role for these autoantibodies. (ii) The
hmAchR M3 is also expressed on different glands; in this
context it is well-known that PBC patients quite often dis-
play an affection of their salivary glands [50]. (iii) Our con-
cept may help to better understand the pathogenesis of
PBC if the autoantibodies exert a functional activity in the
PBC patients as it was shown for the autoantibodies of the
patients with M. Sjögren [26,31,39,40]. Therefore, further
studies will have to focus on the characterization of the
hmAchR M3-specific autoantibodies with respect to an
inhibitory or stimulatory effect on the hmAchR.
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